trending Market Intelligence /marketintelligence/en/news-insights/trending/hni52f9re0zq8lzhe4gjwa2 content esgSubNav
In This List

Depomed names CFO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Depomed names CFO

Depomed Inc. appointed Phillip Donenberg as CFO and senior vice president, effective July 16.

Donenberg will succeed August Moretti, who has served as Depomed's CFO since January 2012.

Previously, Donenberg served as the CFO of AveXis Inc. and played a key role in the recent sale of AveXis to Novartis AG in an $8.7 billion deal.

Newark, Calif.-based Depomed is a specialty pharmaceutical company that engages in the development, sale and licensing of products for pain and other central nervous system conditions in the U.S.